Dermatology

>

Latest News

Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Jennifer Soung, MD, reacts to the FDA approval of roflumilast foam 0.3%

May 22nd 2025

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body psoriasis.

FDA approves roflumilast foam 0.3% for scalp, body psoriasis in adolescents, adults | Image credit: Contemporary Pediatrics
FDA approves roflumilast foam 0.3% for scalp, body psoriasis

May 22nd 2025

FDA approves pz-cel for recessive dystrophic epidermolysis bullosa | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves pz-cel for recessive dystrophic epidermolysis bullosa

April 29th 2025

FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up

April 18th 2025

FDA approves maralixibat tablet formulation for ALGS and PFIC | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves maralixibat tablet formulation for ALGS and PFIC

April 14th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.